Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2008 Jan;5(1):114–122. doi: 10.1016/j.nurt.2007.10.070

Intrathecal pumps

Shawn Belverud 1, Alon Mogilner 1, Michael Schulder 1,✉
PMCID: PMC5084133  PMID: 18164490

Summary

Direct neuroaxis drug delivery has expanded the physician’s armamentarium to provide treatment options to those who have failed more conservative interventions. Starting from Bier’s ‘cocainization of the spinal cord’ in 1898, direct nervous system pharmacy delivery has long been recognized as an effective means to treat pain. Intrathecal pump systems are now commonplace in the management of numerous pain states, as well as of neuromuscular sequelae of central nervous system injury. There has been much advancement in the physiologic and pharmacologic understanding of direct neuromodulation, providing a growing number of treatment options depending on the specific disease state. As well, surgical techniques and catheter systems have undergone refinements providing improved long-term safety and efficacy. We present a review of the historical evolution to current intrathecal therapies, as well as a dialog regarding patient selection, drug options, and side effects. Also, included is a discussion of surgical techniques, current delivery options and complications concerning pump placement.

Key Words: Intradural narcotics, intrathecal narcotics, intraventricular drug delivery, neuropathic pain, nociceptive pain

References

  • 1.Lindsay SM. The conversion challenge: from intrathecal to oral morphine. Am J Hosp Palliat Care. 2004;21:143–147. doi: 10.1177/104990910402100214. [DOI] [PubMed] [Google Scholar]
  • 2.Brill S, Gurman GM, Fisher A. A history of neuraxial administration of local analgesics and opioids. Eur J Anaesthesiol. 2003;20:682–689. doi: 10.1097/00003643-200309000-00002. [DOI] [PubMed] [Google Scholar]
  • 3.Yaksh TL, Rudy TA. Analgesia mediated by a direct spinal action of narcotics. Science. 1976;192:1357–1358. doi: 10.1126/science.1273597. [DOI] [PubMed] [Google Scholar]
  • 4.Simpson RK. Mechanisms or action of intrathecal medications. Neurosurg Clin N Am. 2003;14:353–364. doi: 10.1016/S1042-3680(03)00013-5. [DOI] [PubMed] [Google Scholar]
  • 5.Rico RC, Hobika GH, Avellanosa AM, Trudnowski RJ, Rempel J, West CR. Use of intrathecal and epidural morphine for pain relief in patients with malignant diseases: a preliminary report. J Med. 1982;13:223–231. [PubMed] [Google Scholar]
  • 6.Leavens ME, Hill CS, Cech DA, Weyland JB, Weston JS. Intrathecal and intraventricular morphine for pain in cancer patients: initial study. J Neurosurg. 1982;56:241–245. doi: 10.3171/jns.1982.56.2.0241. [DOI] [PubMed] [Google Scholar]
  • 7.Auld AW, Maki-Jokela A, Murdoch DM. Intraspinal narcotic analgesia in the treatment of chronic pain. Spine. 1985;10:777–781. doi: 10.1097/00007632-198510000-00014. [DOI] [PubMed] [Google Scholar]
  • 8.Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage. 1996;11:71–80. doi: 10.1016/0885-3924(95)00099-2. [DOI] [PubMed] [Google Scholar]
  • 9.Nitescu P, Dahm P, Appelgren L, Curelaru I. Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of “refractory” nonmalignant pain. Clin J Pain. 1998;14:17–28. doi: 10.1097/00002508-199803000-00004. [DOI] [PubMed] [Google Scholar]
  • 10.Brogan SE. Intrathecal therapy for the management of cancer pain. Curr Pain Headache Rep. 2006;10:254–259. doi: 10.1007/s11916-006-0029-8. [DOI] [PubMed] [Google Scholar]
  • 11.Kaplan KM, Brose WG. Intrathecal methods. Neurosurg Clin N Am. 2004;15:289–296. doi: 10.1016/j.nec.2004.02.011. [DOI] [PubMed] [Google Scholar]
  • 12.Brazenor GA. Long term intrathecal administration of morphine: a comparison of bolus injection via reservoir with continuous infusion by implanted pump. Neurosurg. 1987;21:484–491. doi: 10.1227/00006123-198710000-00008. [DOI] [PubMed] [Google Scholar]
  • 13.Krames E. Implantable devices for pain control: spinal cord stimulation and intrathecal therapies. Best Pract Res Clin Anaesthesiol. 2002;16:619–649. doi: 10.1053/bean.2002.0263. [DOI] [PubMed] [Google Scholar]
  • 14.Penn RD. Intrathecal medication delivery. Neurosurg Clin N Am. 2003;14:381–387. doi: 10.1016/S1042-3680(03)00016-0. [DOI] [PubMed] [Google Scholar]
  • 15.Hassenbusch SJ, Paice JA, Patt RB, Bedder MD, Bell GK. Clinical realities and economic considerations: economics of intrathecal therapy. J Pain Symptom Manage. 1997;14:S36–S48. doi: 10.1016/S0885-3924(97)00169-3. [DOI] [PubMed] [Google Scholar]
  • 16.France JC, Jorgenson SS, Lowe TG, Dwyer AP. The use or intrathecal morphine for analgesia after posterolateral lumbar fusion: a prospective, double-blind, randomized study. Spine. 1997;22:2272–2277. doi: 10.1097/00007632-199710010-00015. [DOI] [PubMed] [Google Scholar]
  • 17.Jacobson L, Chabal C, Brody MC. A dose-response study of intrathecal morphine: efficacy, duration, optimal dose and side effects. Anesth Analg. 1988;67:1082–1088. [PubMed] [Google Scholar]
  • 18.Anderson VC, Cooke B, Burchiel KJ. Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. Pain Med. 2001;2:287–297. doi: 10.1046/j.1526-4637.2001.01052.x. [DOI] [PubMed] [Google Scholar]
  • 19.Uppal GS, Haider TT, Dwyer A, Uppal JA. Reversible urinary retention secondary to excessive morphine delivered by an intrathecal morphine pump. Spine. 1994;19:719–720. doi: 10.1097/00007632-199403001-00013. [DOI] [PubMed] [Google Scholar]
  • 20.Abs R, Verfielst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–2222. doi: 10.1210/jc.85.6.2215. [DOI] [PubMed] [Google Scholar]
  • 21.Aldrete JA, Couto da Silva JM. Leg edema from intrathecal opiate infusions. Eur J Pain. 2000;4:361–365. doi: 10.1053/eujp.2000.0199. [DOI] [PubMed] [Google Scholar]
  • 22.Yaksh TL, Kohl RL, Rudy TA. Induction of tolerance and withdrawal in rats receiving morphine in the spinal subarachnoid space. Eur J Pharmacol. 1977;4:275–284. doi: 10.1016/0014-2999(77)90294-1. [DOI] [PubMed] [Google Scholar]
  • 23.Wermeling DP, Berger JR. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Pharmacotherapy. 2006;26:395–402. doi: 10.1592/phco.26.3.395. [DOI] [PubMed] [Google Scholar]
  • 24.Hassenbusch SJ, Gunes S, Wachsman S, Willis KD. Intrathecal clonidine in the treatment of intractable pain: a phase I/II study. Pain Med. 2002;3:85–91. doi: 10.1046/j.1526-4637.2002.02014.x. [DOI] [PubMed] [Google Scholar]
  • 25.Hassenbusch SJ, Portenoy RK, Cousins M, et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery—report of an expert panel. J Pain Symptom Manage. 2004;27:540–563. doi: 10.1016/j.jpainsymman.2004.03.001. [DOI] [PubMed] [Google Scholar]
  • 26.Rice GW, Wilkin GP, Tumbull MJ, Bowery NG. Are baclofensensitive GABAB receptors present on primary afferent terminals of the spinal cord? Nature. 1984;301:71–74. doi: 10.1038/307071a0. [DOI] [PubMed] [Google Scholar]
  • 27.Kerr DIB, Ong J. GABAB receptors. Pharmacol Ther. 1995;67:187–246. doi: 10.1016/0163-7258(95)00016-A. [DOI] [PubMed] [Google Scholar]
  • 28.Zieglgänsberger W, Howe JF, Sutor B. The neuropharmacology of baclofen. In: Müller H, Zierski J, Penn RD, editors. Local-spinal therapy of spasticity. Berlin: Springer-Verlag; 1988. pp. 37–49. [Google Scholar]
  • 29.Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts) N Engl J Med. 1981;304:96–99. doi: 10.1056/NEJM198105143042010. [DOI] [PubMed] [Google Scholar]
  • 30.Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet. 1984;1(8385):1078–1078. doi: 10.1016/S0140-6736(84)91487-9. [DOI] [PubMed] [Google Scholar]
  • 31.Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989;320:1517–1521. doi: 10.1056/NEJM198906083202303. [DOI] [PubMed] [Google Scholar]
  • 32.Dralle D, Müller H, Zierski J, Klug N. Intrathecal baclofen for spasticity. Lancet. 1985;2(8462):1003–1003. doi: 10.1016/S0140-6736(85)90541-0. [DOI] [PubMed] [Google Scholar]
  • 33.Müller H. Treatment of severe spasticity: results of multi-center trial conducted in Germany involving the intrathecal infusion of baclofen by an implantable drug delivery system. Dev Med Child Neurol. 1992;34:739–745. [Google Scholar]
  • 34.Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA. 1991;265:1418–1422. doi: 10.1001/jama.265.11.1418. [DOI] [PubMed] [Google Scholar]
  • 35.Bleyenheuft C, Filipetti P, Caldas C, Lejeune T. Experience with external pump trial prior to implantation for intrathecal baclofen in ambulatory patients with spastic cerebral palsy. Neurophysiol Clin. 2007;37:23–28. doi: 10.1016/j.neucli.2007.01.004. [DOI] [PubMed] [Google Scholar]
  • 36.Armstrong RW, Steinbok P, Cochrane DD, Kube SD, Fife SE, Farrell K. Intrathecally administered baclofen for the treatment of children with spasticity of cerebral origin. J Neurosurg. 1997;87:409–414. doi: 10.3171/jns.1997.87.3.0409. [DOI] [PubMed] [Google Scholar]
  • 37.Albright AL, Barry MJ, Shafton DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol. 2001;43:652–657. doi: 10.1017/S0012162201001190. [DOI] [PubMed] [Google Scholar]
  • 38.Albright AL. Neurosurgical treatment of spasticity and other pediatric movement disorders. J Child Neurol. 2003;18(Suppl 1):S67–S78. doi: 10.1177/0883073803018001S0801. [DOI] [PubMed] [Google Scholar]
  • 39.Ivanhoe CB, Francisco GE, McGuire JR, Subramanian T, Grissom SP. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil. 2006;87:1509–1515. doi: 10.1016/j.apmr.2006.08.323. [DOI] [PubMed] [Google Scholar]
  • 40.Ben Smail D, Peskine A, Proche N, Mailhan L, Thiébaut I, Bussel B. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler. 2006;12:101–103. doi: 10.1191/1352458506ms1232sr. [DOI] [PubMed] [Google Scholar]
  • 41.Muller H, Zierski J, Dralle D, et al. Pharmacokinetics of intrathecal baclofen. In: Muller H, Zierski J, Penn RD, et al., editors. Local-spinal therapy of spasticity. Berlin: Springer-Verlag; 1988. pp. 155–214. [Google Scholar]
  • 42.Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991;1418–1422. [PubMed]
  • 43.Kofler M, Kronenberg MF, Rifici C, Saltuari L, Bauer G. Epileptic seizures associated with intrathecal baclofen application. Neurology. 1994;44:25–27. doi: 10.1212/wnl.44.1.25. [DOI] [PubMed] [Google Scholar]
  • 44.Buonaguro V, Scelsa B, Curci D, Monforte S, Iuorno T, Motta F. Epilepsy and intrathecal baclofen therapy in children with cerebral palsy. Pediatric Neurology. 2005;33:110–113. doi: 10.1016/j.pediatrneurol.2005.03.002. [DOI] [PubMed] [Google Scholar]
  • 45.Sansone JM, Mann D, Noonan K, Mcleish D, Ward M, Iskandar BJ. Rapid progression of scoliosis following insertion of intrathecal baclofen pump. J Pediatric Orthop. 2006;26:125–128. doi: 10.1097/01.bpo.0000191555.11326.bd. [DOI] [PubMed] [Google Scholar]
  • 46.Albright AL, Turner M, Pattisapu JV. Best-practice surgical techniques for intrathecal baclofen therapy. J Neurosurg. 2006;104:233–239. doi: 10.3171/jns.2006.104.2.233. [DOI] [PubMed] [Google Scholar]
  • 47.McCall TD, MacDonald JD. Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery. 2006;59:634–640. doi: 10.1227/01.NEU.0000227570.40402.77. [DOI] [PubMed] [Google Scholar]
  • 48.Kopell BH, Sala D, Doyle WK, Feldman DS, Wisoff JH, Weiner HL. Subfascial implantation of intrathecal baclofen pumps in children: technical note. Neurosurgery. 2001;49:753–756. doi: 10.1097/00006123-200109000-00045. [DOI] [PubMed] [Google Scholar]
  • 49.Huntoon MA, Hurdle MF, Marsh RW, Reeves RK. Intrinsic spinal cord catheter placement: implications of new intractable pain in a patient with a spinal cord injury. Anesth Analg. 2004;99:1763–1765. doi: 10.1213/01.ANE.0000136421.69976.AE. [DOI] [PubMed] [Google Scholar]
  • 50.Atiyeh BS, Hayek SN, Skaf GS, Al Araj A, Chamoun RB. Baclofen pump pocket infection: a case report of successful salvage with muscle flap. Int Wound J. 2006;3:23–28. doi: 10.1111/j.1742-4801.2006.00179.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Boviatsis EJ, Kouyialis AT, Boutsikakis I, Korfias S, Sakas DE. Infected CNS infusion pumps, Is there a chance for treatment without removal? Acta Neurochir (Wien) 2004;146:463–467. doi: 10.1007/s00701-004-0217-4. [DOI] [PubMed] [Google Scholar]
  • 52.Shirley KW, Kothare S, Piatt JH, Adirim TA. Intrathecal baclofen overdose and withdrawal. Pediatr Emerg Care. 2006;22:258–261. doi: 10.1097/01.pec.0000210175.40763.c5. [DOI] [PubMed] [Google Scholar]
  • 53.Greenberg MI, Hendrickson RG. Baclofen withdrawal following removal of an intrathecal baclofen pump despite oral baclofen replacement. J Toxicol Clin Toxicol. 2003;41:83–85. doi: 10.1081/CLT-120018277. [DOI] [PubMed] [Google Scholar]
  • 54.Wadhwa RK, Shaya MR, Nanda A. Spinal cord compression in a patient with a pain pump for failed back syndrome: a chalk-like precipitate mimicking a spinal cord neoplasm: case report. Neurosurgery. 2006;58:E387–E387. doi: 10.1227/01.NEU.0000195070.41751.62. [DOI] [PubMed] [Google Scholar]
  • 55.Bejjani GK, Karim NO, Tzortzidis F. Intrathecal granuloma after implantation of a morphine pump: case report and review of the literature. Surg Neurol. 1997;48:288–291. doi: 10.1016/S0090-3019(96)00466-1. [DOI] [PubMed] [Google Scholar]
  • 56.Miele VJ, Price KO, Bloomfield S, Hogg J, Bailes JE. A review of intrathecal morphine therapy related granulomas. Eur J Pain. 2006;10:251–261. doi: 10.1016/j.ejpain.2005.05.002. [DOI] [PubMed] [Google Scholar]
  • 57.Lew SM, Psaty EL, Abbott R. An unusual cause of overdose after baclofen pump implantation: case report. Neurosurgery. 2005;56:E624–E624. doi: 10.1227/01.NEU.0000154133.49781.66. [DOI] [PubMed] [Google Scholar]
  • 58.Lazorthes Y, Verdic JC, Bastide R, Lavados A, Descouens D. Spinal versus intraventricular chronic opiate administration with implantable drug delivery devices for cancer pain. Appl Neurophysiol. 1985;48:234–241. doi: 10.1159/000101133. [DOI] [PubMed] [Google Scholar]
  • 59.Lazorthes YR, Sallerin BAM, Verdié JCP. Intracerebroventricular administration of morphine for control of irreducible cancer pain. Neurosurgery. 1995;37:422–429. doi: 10.1227/00006123-199509000-00009. [DOI] [PubMed] [Google Scholar]
  • 60.Dennis GC, DeWitty RL. Long-term intraventricular infusion of morphine for intractable pain in cancer of the head and neck. Neurosurgery. 1990;26:404–407. doi: 10.1097/00006123-199003000-00005. [DOI] [PubMed] [Google Scholar]
  • 61.Karavelis A, Foroglou G, Selviaridis P, Fountzilas G. Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. Neurosurgery. 1996;39:57–61. doi: 10.1097/00006123-199607000-00012. [DOI] [PubMed] [Google Scholar]
  • 62.Baskin DS, Browning JL, Pirozzolo FJ, Korporaal S, Baskin JA, Appel SH. Brain choline acetyltransferase and mental function in Alzheimer disease. Arch Neurol. 1999;56:1121–1123. doi: 10.1001/archneur.56.9.1121. [DOI] [PubMed] [Google Scholar]
  • 63.Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brain of β-glucuronidase-deficient mice. J Virol. 2003;77:7034–7040. doi: 10.1128/JVI.77.12.7034-7040.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Dohura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol. 2004;78:4999–5006. doi: 10.1128/JVI.78.10.4999-5006.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES